Hung Trinh: Researchers Develop a Potential “Universal” CAR T-Cell Therapy for Blood Cancers

Hung Trinh, Director of Process Development and MFG Science and Technology at Vyriad, posted on LinkedIn:

“Researchers Develop a Potential ‘Universal’ CAR T-Cell Therapy for Blood Cancers, by National Cancer Institute (NCI)
Acute myeloid leukemia (AML) cells floating among other cells. Researchers have developed an approach to CAR T-cell therapy that can potentially treat nearly any blood cancer, including AML.

Credit: iStock

In the Lord of the Rings, there was “one ring to rule them all.” Now, a team of researchers is developing their own single ruler, an approach to CAR T-cell therapy that could treat all forms and types of blood cancer.

In experiments in mouse models of different blood cancers, the treatment rapidly eliminated tumors, including in mice with acute myeloid leukemia (AML), a difficult-to-treat type of blood cancer for which researchers have struggled to develop effective immunotherapies.

There was also no evidence of serious side effects in the animals. And, finally—and distinctly from the standard approach to current CAR T-cell therapies—it provided the mice with a healthy supply of new blood cells.

Results from the study were published August 31 in Science Translational Medicine.

Developed by a research team at the University of Pennsylvania Perelman School of Medicine, the treatment relies on a newer form of the gene-editing technology CRISPR, called base editing. View the publication.”

Further reading.
Source: Hung Trinh/LinkedIn